BioPharma Resources

Drug Trial Radar · NCT07869043

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Jun 7, 2029

Study completion Aug 30, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Conditions

  • Asthma

Interventions

  • tilrekimigDrug

    subcutaneous injection

  • PlaceboOther

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized asthma exacerbation rate over 52 weeksTime frame: Baseline through Week 52

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Asthma and Allergy Center of Chicago

    River Forest, Illinois · Recruiting

  • Hannibal Regional Healthcare System, Inc.

    Hannibal, Missouri · Not yet recruiting

  • Urban Health Plan

    The Bronx, New York · Not yet recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Not yet recruiting

  • Allergy and Clinical Immunology Associates

    Pittsburgh, Pennsylvania · Recruiting

  • Orion Clinical Research

    Austin, Texas · Recruiting

  • Southwest Medical Center (Building I) aka Southwest Family Medicine Associates

    Dallas, Texas · Not yet recruiting

  • A & A Research Consultants, LLC

    Edinburg, Texas · Not yet recruiting

  • Western Sky Medical Research

    El Paso, Texas · Not yet recruiting

  • Pulmonary and Sleep Center of the Valley

    McAllen, Texas · Not yet recruiting

  • DM Clinical Research

    Tomball, Texas · Recruiting

  • Solace Clinical Research

    Bayamón, Puerto Rico · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.